Back to News
Market Impact: 0.35
AstraZeneca PLC Announces US FDA Accelerated Approval of Ultomiris for IgAN on 22 October 2026
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AstraZeneca said the US approved Alexion’s Ultomiris (ravulizumab) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. The article text is truncated after saying the indication was approved under “acceler…,” so the approval pathway and any additional details are not available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
AZN0.75
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- SpaceX records $561 million investment gain from stake in Elon Musk's Boring Co.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More